

CIRM Funded Clinical Trials

Phase I Study of IL13R α 2-Targeting CAR T Cells After Lymphodepletion for Children with Refractory or Recurrent Malignant Brain Tumors

Disease Area:	Brain Cancer
Investigator:	Leo Wang
Institution:	City of Hope, Beckman Research Institute
CIRM Grant:	CLIN2-12153 (Pre-Active)
Award Value:	\$8,401,309
Trial Sponsor:	Beckman Research Institute of City of Hope
Trial Stage:	Phase 1
Trial Status:	Recruiting
Targeted Enrollment:	18
ClinicalTrials.gov ID:	NCT04510051



Leo Wang

Details:

City of Hope will conduct a clinical trial for children with malignant brain tumors. Brain tumors are the most common solid tumor of childhood, with roughly 5,000 new diagnoses per year in the United States.

The team will treat pediatric patients with aggressive brain tumors using chimeric antigen receptor (CAR) T cell therapy. The CAR T therapy involves obtaining a patient's own T cells, which are an immune system cell that can destroy foreign or abnormal cells, and modifying them so that they are able to identify and destroy the brain tumors. The aim of this approach is to improve patient outcome.

Design:

Phase 1 Clinical Trial

Goal:

Demonstrate safety and tolerability.

[Contact Trial Sponsor](#)

Source URL: <https://www.cirm.ca.gov/clinical-trial/phase-i-study-il13r%CE%B12-targeting-car-t-cells-after-lymphodepletion-children-refractory>